RedHill Biopharma Ltd (RDHL)

[midastouch017]

]HC Wainwright Reiterates “Buy” Rating for RedHill Biopharma (NASDAQ:RDHL)

https://zolmax.com/investing/hc-wainwright-reiterates-buy-rating-for-redhill-biopharma-nasdaqrdhl/6235817.html

Posted by John Perry on Sep 1st, 2021

RedHill Biopharma logoRedHill Biopharma (NASDAQ:RDHL)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Monday, TipRanks reports. They presently have a $23.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 127.72% from the stock’s previous close.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Ibex Investors LLC boosted its stake in shares of RedHill Biopharma by 17.1% during the first quarter. Ibex Investors LLC now owns 2,216,793 shares of the biotechnology company’s stock worth $16,227,000 after buying an additional 324,200 shares during the period. Disciplined Growth Investors Inc. MN boosted its stake in shares of RedHill Biopharma by 8.1% during the second quarter. Disciplined Growth Investors Inc. MN now owns 1,976,476 shares of the biotechnology company’s stock worth $13,598,000 after buying an additional 147,889 shares during the period. ARK Investment Management LLC lifted its position in RedHill Biopharma by 1.5% in the second quarter. ARK Investment Management LLC now owns 787,469 shares of the biotechnology company’s stock valued at $5,418,000 after purchasing an additional 11,771 shares during the period. Great Point Partners LLC acquired a new stake in RedHill Biopharma in the first quarter valued at about $5,163,000. Finally, DAFNA Capital Management LLC acquired a new stake in RedHill Biopharma in the first quarter valued at about $3,337,000. Institutional investors and hedge funds own 19.96% of the company’s stock.